EU novel foods: where NMN, urolithin A and spermidine stand in June 2026
A plain-English status update on the three most-asked novel food ingredients in EU supplements, and what brands can actually launch this quarter.
Every week brands ask Jake the same question: can I sell NMN, urolithin A or spermidine in the EU right now? Here is the practical answer as of June 2026, no legalese.
NMN (β-nicotinamide mononucleotide)
Still treated as an unauthorised novel food in the EU. National enforcement varies. France and Belgium are actively pulling listings, the Netherlands and Czech Republic look the other way for now. If you are building a brand for 2027, do not anchor the SKU on NMN unless you are prepared to pivot to NR or trans-resveratrol.
Urolithin A
Authorised. Mitopure (Amazentis) holds the novel food approval with a specific use level. You can launch in capsules and gummies at the approved dose. Generic urolithin A from non-licensed suppliers is not covered, even if the molecule is identical.
Spermidine
Wheat-germ extracts standardised to spermidine are sold under traditional food status by several EU manufacturers. Synthetic spermidine trihydrochloride is novel and not authorised. If a supplier offers you 'pure spermidine', ask whether it is wheat-germ-derived and request the EFSA dossier reference.
What Jake recommends
For a 2026 EU launch in the longevity category, the safe stack is urolithin A (licensed), trans-resveratrol, fisetin, and quercetin phytosome. All four have settled regulatory status and multiple EU contract manufacturers can run them at 5k bottles.
Tell Jake what you need. Real EU supplier offers within a day.